Overview

MRSA Decolonization in Complicated Carriage - Cluster Randomized Trial

Status:
Not yet recruiting

Trial end date:
2024-04-01

Target enrollment:
0

Participant gender:
All

Summary

Multicenter open-label cluster randomized controlled trial determining the superiority of doxycycline-rifampicin compared to trimethoprim-rifampicin for the decolonization treatment of complicated MRSA carriership.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Leiden University Medical Center

Treatments:

Doxycycline
Rifampin
Trimethoprim

Criteria

Inclusion Criteria:

- Age ≥18 years

- Complicated MRSA carriership. Complicated carriership is defined as having one of the
following features: (i) the presence of MRSA located at another site than the nose,
(ii) an active infection with MRSA, (iii) in vitro resistance for mupirocin, (iv)
active skin lesions, (v) foreign material that connects an internal body site with the
outside (e.g., urine catheter, external fixation material), (vi) previously failure of
decolonization treatment.

In case of none of the previously mentioned features, this is considered uncomplicated
carriership.

- The ability to provide informed consent for the use of their data.

Exclusion Criteria:

- - Presence of any iv-access, urinary catheters or drains (because of high risk of
treatment failure)

- Failure of previous decolonization attempt of complicated MRSA carriage

- Allergy or other contra-indication to either doxycycline, rifampicin or trimethoprim
(these patients will participate in the observational arm)

- Previous participation in this study (every patient can only participate once)

- Pregnancy